Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (17981)	2/16/2004 9:22:18 PM
From: JoeinIowa	Read Replies (2) \| Respond to of 120415

Gary, We have a short term and a long term portfolio on the Yeehaw thread. This is the long term thread which I have asked ESIM to be added to. We also have a shorter term trading thread which was started a few months ago since trading seems to be back in vogue. Subject 52131 I keep the stats for the long term thread and we have done pretty well over the last 15 months. The selections come from a wide range of different investment types. All are welcome to participate. Joe

To: GARY P GROBBEL who wrote (17981)	2/17/2004 8:14:51 AM
From: Findit	Read Replies (1) \| Respond to of 120415

Gary BSDM news should help today. SALT LAKE CITY, Feb. 17 /PRNewswire-FirstCall/ -- BSD Medical Corp. (OTC Bulletin Board: BSDM - News) today announced that it has received FDA approval to market a new microwave generator that the company has designed to provide significantly better treatment of prostate, cervical, breast, and head and neck cancers through interstitial hyperthermia therapy. This new generator supports advanced treatment steering through electronic phase control, a powerful capability engineered and patented by BSD Medical Corp. Electronic phase control allows an operator to electronically direct and shape the pattern of hyperthermia treatments based on the positioning of the microwave antennae array used in treating the tumor. The treatment pattern can thereby be electronically targeted on the tumor position, shape and size. ADVERTISEMENT This FDA approval concludes the final phase of the commercial introduction of four new cancer treatment systems for sale the United States by BSD Medical Corporation. The systems, empowered by these new features, revolutionize the treatment of cancer patients using superficial and interstitial hyperthermia therapy. They were six years in planning and development -- an extensive effort inspired by the 1996 publication of a Johns Hopkins Hospital study in CANCER (the official journal of the American Cancer Society), which concluded that interstitial hyperthermia was convenient, safe and effective in treating human cancers (see CANCER, June 1, 1996, pp. 2363-2370). Numerous other studies have provided further support. The new BSD-500i-4, BSD-500c-4, BSD-500i-8 and BSD-500c-8 bear little resemblance to anything previously seen in hyperthermia systems. They are compact, portable and ergonomically engineered for use in a demanding hospital environment. A high-resolution graphic touch-screen display drives the new systems and supports pretreatment planning, including planning with electronic phase control, upstaging anything ever before used in operator control for similar applications. The BSD-500 family of systems is capable of providing both superficial and interstitial hyperthermia cancer therapy. In addition to the capacity for treating cancers accessible through interstitial treatment, superficial hyperthermia is used to non-invasively treat cancerous tumors located within a few centimeters of the surface of the body, such as melanoma and recurrent breast cancer. BSD Medical has FDA market approval for superficial hyperthermia treatment, and owns the rights to all FDA market approvals that have been issued to treat cancer using microwave interstitial hyperthermia. For further information about BSD Medical and hyperthermic oncology, visit ( www.bsdmc.com ). Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's filings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results. -------------------------------------------------------------------------------- Source: BSD Medical Corp.